Cero Therapeutics Holdings, Inc. financial data

Symbol
CERO, CEROW on Nasdaq
Location
201 Haskins Way, Suite 230, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 52.1 %
Debt-to-equity -434 % -595%
Return On Equity 529 % +1582%
Return On Assets -158 % -153%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.38M shares -63.5%
Common Stock, Shares, Outstanding 5.85K shares
Entity Public Float 5.77M USD +114%
Common Stock, Value, Issued 1 USD -98.9%
Weighted Average Number of Shares Outstanding, Basic 3.43M shares +2329%
Weighted Average Number of Shares Outstanding, Diluted 3.43M shares +2329%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.32M USD +101%
General and Administrative Expense 8.28M USD +89.7%
Operating Income (Loss) -16.6M USD -95.2%
Nonoperating Income (Expense) 5.49M USD +98.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -308K USD -313%
Income Tax Expense (Benefit) 25.8K USD -57.4%
Net Income (Loss) Attributable to Parent -11.1M USD -93.5%
Earnings Per Share, Basic -8 USD/shares +93.2%
Earnings Per Share, Diluted -8 USD/shares +93.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.1M USD
Assets, Current 5.77M USD +4.85%
Property, Plant and Equipment, Net 452K USD -47%
Operating Lease, Right-of-Use Asset 1.27M USD -36.9%
Assets 7.99M USD -11.7%
Accounts Payable, Current 6.38M USD -9.64%
Employee-related Liabilities, Current 61.1K USD -50.4%
Accrued Liabilities, Current 470K USD +59.6%
Liabilities, Current 7.86M USD -32.5%
Operating Lease, Liability, Noncurrent 462K USD -66.2%
Liabilities 8.32M USD -36.2%
Retained Earnings (Accumulated Deficit) -76M USD -17.1%
Stockholders' Equity Attributable to Parent -329K USD +91.7%
Liabilities and Equity 7.99M USD -11.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -198K USD +35.8%
Net Cash Provided by (Used in) Investing Activities -100K USD
Common Stock, Shares Authorized 45.4M shares
Common Stock, Shares, Issued 5.85K shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -298K USD +3.35%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.33M USD +108%
Deferred Tax Assets, Valuation Allowance 17.6M USD +29.7%
Deferred Tax Assets, Gross 17.6M USD +29.7%
Operating Lease, Liability 1.37M USD -36.8%
Depreciation 76.3K USD +0.01%
Lessee, Operating Lease, Liability, to be Paid 1.47M USD -39.7%
Property, Plant and Equipment, Gross 2.55M USD
Operating Lease, Liability, Current 905K USD +13.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 726K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 726K USD -26.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 105K USD -62.3%
Deferred Tax Assets, Operating Loss Carryforwards 12.2M USD +34.9%
Preferred Stock, Shares Issued 4M shares
Deferred Federal Income Tax Expense (Benefit) 182K USD
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 538K USD +17.2%
Additional Paid in Capital 73.3M USD +35.8%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.14M USD +239%
Interest Expense 14.4K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%